Could a supplement and drug combo help treat obesity?
NCT ID NCT05713799
First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 4 times
Summary
This Phase 2 trial tests whether combining the supplement alpha-lipoic acid with the drug mirabegron can improve how the body processes sugar in people with obesity. Sixty adults aged 18 to 65 with a BMI between 30 and 45 will take the combination or a placebo for 4 weeks. The study measures changes in insulin sensitivity to see if this approach could lead to a new treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
alpha-lipoic acid and mirabegron
What this could lead to
If it works, this could point toward a new combination treatment for obesity and insulin resistance that is safe and widely available.
What could go wrong
This is an early Phase 2 trial with only 60 participants, so results may not apply to everyone. The combination may not improve insulin sensitivity more than placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••